コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 insulin C-peptide, glycated hemoglobin, and homeostasis model assessment of insulin resistance.
2 rence, and insulin resistance assessed using homeostasis model assessment of insulin resistance.
3 d fat mass, body weight, plasma insulin, and homeostasis model assessment of insulin resistance.
4 ivity was estimated by the Matsuda Index and homeostasis model assessment of insulin resistance.
5 ermine basal levels of insulin, glucose, and homeostasis model assessment of insulin resistance.
6 nonesterified fatty acids; insulin; and the homeostasis model assessment of insulin resistance.
7 ss (NAD[P]H quinone oxidoreductase mRNA) and homeostasis model assessment of insulin resistance.
8 insulin resistance measures (log-transformed homeostasis model assessment of insulin resistance 0.65
9 U/L; P = 0.03) and insulin resistance (Delta homeostasis model assessment of insulin resistance: -0.3
10 check index (0.348 [0.332-0.375]) and median homeostasis model assessment of insulin resistance (1.13
11 levels of fasting insulin (11.3 micro U/ml), homeostasis model assessment of insulin resistance (2.7)
12 justed, P = 0.04 and P < 0.05, respectively; homeostasis model assessment of insulin resistance adjus
13 lood pressure, diastolic blood pressure, and homeostasis model assessment of insulin resistance, afte
15 ference] and glucose and insulin metabolism (homeostasis model assessment of insulin resistance and f
16 lucose, fasting insulin, insulin resistance (homeostasis model assessment of insulin resistance) and
17 sis model assessment of insulin sensitivity, homeostasis model assessment of insulin resistance, and
18 ysical activity, family history of diabetes, homeostasis model assessment of insulin resistance, and
19 ), fasting blood glucose and insulin levels, homeostasis model assessment of insulin resistance, and
20 riacylglycerol, glucose, insulin, C-peptide, homeostasis model assessment of insulin resistance, and
21 red glucose tolerance), waist circumference, homeostasis model assessment of insulin resistance, and
22 n, insulin 2 h after oral glucose challenge, homeostasis model assessment of insulin resistance, BMI,
23 asting plasma insulin concentration, and the homeostasis model assessment of insulin resistance but w
24 d pressure, fasting insulin and glucose, and homeostasis model assessment of insulin resistance] by u
25 ronger among those in the highest tertile of homeostasis model assessment of insulin resistance compa
26 ciated with higher insulin resistance index (homeostasis model assessment of insulin resistance) duri
27 Secondary endpoints included change in homeostasis model assessment of insulin resistance; fast
28 ty, by gas chromatography-mass spectrometry, homeostasis model assessment of insulin resistance, hepa
29 ein intake and offspring fasting insulin and homeostasis model assessment of insulin resistance (HOMA
30 The homeostasis model assessment of insulin resistance (HOMA
31 ietary SFA:carbohydrate ratio intake for the homeostasis model assessment of insulin resistance (HOMA
32 ment of beta cell function (HOMA-B), and the homeostasis model assessment of insulin resistance (HOMA
33 group had significant glycemic improvement [homeostasis model assessment of insulin resistance (HOMA
34 ; 95% CI: -6.41, 4.84 pmol/L; P = 0.78), the homeostasis model assessment of insulin resistance (HOMA
35 LA, EPA plus DHA, and total n-3 FAs) and the homeostasis model assessment of insulin resistance (HOMA
36 he high-dairy diet (P < 0.05) as assessed by homeostasis model assessment of insulin resistance (HOMA
37 women with normal insulin sensitivity [i.e., homeostasis model assessment of insulin resistance (HOMA
38 assified by different IR levels according to homeostasis model assessment of insulin resistance (HOMA
39 At the end of the trial, fasting insulin and homeostasis model assessment of insulin resistance (HOMA
40 ulin (PI), glycated hemoglobin (Hb A1c), and homeostasis model assessment of insulin resistance (HOMA
41 tion study for fasting glucose, insulin, and homeostasis model assessment of insulin resistance (HOMA
42 s on changes in weight, fasting insulin, and homeostasis model assessment of insulin resistance (HOMA
43 The index for homeostasis model assessment of insulin resistance (HOMA
44 e aminotransferase (AST), platelets, and the homeostasis model assessment of insulin resistance (HOMA
45 olume, cognition, and insulin sensitivity by homeostasis model assessment of insulin resistance (HOMA
46 Insulin resistance was measured using homeostasis model assessment of insulin resistance (HOMA
47 We assessed the progress in fasting insulin, homeostasis model assessment of insulin resistance (HOMA
48 s, serum glucose and insulin concentrations, homeostasis model assessment of insulin resistance (HOMA
49 Index (QUICKI), fasting serum insulin (FSI), homeostasis model assessment of insulin resistance (HOMA
50 The homeostasis model assessment of insulin resistance (HOMA
51 sphatase, gamma glutamyl transpeptidase, and homeostasis model assessment of insulin resistance (HOMA
52 l-glucose-tolerance test (OGTT) insulin, the homeostasis model assessment of insulin resistance (HOMA
53 the basis of a score of more than 3.0 on the homeostasis model assessment of insulin resistance (HOMA
54 r necrosis factor receptor-2, as well as the homeostasis model assessment of insulin resistance (HOMA
55 Change in weight, BMI, body fat, and homeostasis model assessment of insulin resistance (HOMA
56 resistance was measured with the use of the homeostasis model assessment of insulin resistance (HOMA
57 while indices of insulin resistance included homeostasis model assessment of insulin resistance (HOMA
58 Homeostasis model assessment of insulin resistance (HOMA
59 Insulin resistance, assessed by tertile of homeostasis model assessment of insulin resistance (HOMA
60 d free fatty acids (FFAs) were measured, and homeostasis model assessment of insulin resistance (HOMA
61 P), and interleukin 6 (IL-6), as well as the homeostasis model assessment of insulin resistance (HOMA
62 Insulin resistance was measured by the homeostasis model assessment of insulin resistance (HOMA
63 The homeostasis model assessment of insulin resistance (HOMA
64 longer significant) after adjustment for the homeostasis model assessment of insulin resistance (HOMA
65 ing glucose, and insulin concentrations, and Homeostasis Model Assessment of Insulin Resistance [HOMA
66 (fasting insulin beta = -0.1467, P = 0.010; homeostasis model assessment of insulin resistance [HOMA
67 d HbA1c and of ALT with fasting insulin (and homeostasis model assessment of insulin resistance [HOMA
68 f body adiposity (BMI), insulin sensitivity (homeostasis model assessment of insulin resistance [HOMA
69 sion tomography, in seven insulin-sensitive (homeostasis model assessment of insulin resistance [HOMA
70 mference, and insulin resistance (by updated homeostasis model assessment of insulin resistance; HOMA
71 lin resistance (measured with the use of the homeostasis model assessment of insulin resistance), ind
72 Adjustment for body composition, homeostasis model assessment of insulin resistance index
73 including lower visceral fat, liver fat, and homeostasis model assessment of insulin resistance index
74 , P<0.0001), PICP (beta=-0.31, P<0.0001) and homeostasis model assessment of insulin resistance index
75 ases in plasma fasting glucose, insulin, and homeostasis model assessment of insulin resistance indic
76 In the validation NAFLD cohort, homeostasis model assessment of insulin resistance, insu
78 ificantly lowered fasting plasma glucose and homeostasis model assessment of insulin resistance level
79 2.27+/- 0.76; DM: 1.68 +/- 0.76; P = 0.003), homeostasis model assessment of insulin resistance (LM:
80 mU/L; DBs: -1.78 +/- 1.25 mU/L, P < 0.001), homeostasis model assessment of insulin resistance (mean
81 6, P = 0.01; women R = 0.40, P = 0.004), and homeostasis model assessment of insulin resistance (men
82 th C-reactive protein in both sexes and with homeostasis model assessment of insulin resistance only
83 ln(insulin) (P = 0.001), lower ln(HOMA-IR) (homeostasis model assessment of insulin resistance) (P =
84 l/L, LF = -0.31 +/- 0.11 mmol/L; P = 0.018), homeostasis model assessment of insulin resistance (PY =
85 in telomere length were correlated with the homeostasis model assessment of insulin resistance (r=-0
86 rrelated positively with insulin resistance (homeostasis model assessment of insulin resistance: r =
87 tabolic syndrome variables (body mass index, homeostasis model assessment of insulin resistance, rati
88 raction=2.48x10(-11) for fasting insulin and homeostasis model assessment of insulin resistance, resp
89 Homeostasis model assessment of insulin resistance score
90 (HbA1c), plasma glucose, insulin levels, and homeostasis model assessment of insulin resistance score
91 elevated insulin levels (P = 0.001), higher homeostasis model assessment of insulin resistance score
92 ), percentage of body fat, glucose, insulin, homeostasis model assessment of insulin resistance, seru
93 ter adjusting for age, sex, fasting glucose, homeostasis model assessment of insulin resistance, syst
94 adjustment (P < 0.001) but not with glucose, homeostasis model assessment of insulin resistance, the
95 ations of C-reactive protein, interleukin-6, homeostasis model assessment of insulin resistance, trig
96 o produced an increase of 0.8 +/- 0.9 in the homeostasis model assessment of insulin resistance, wher
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。